Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.
- Revenue
- +77,677.8%
- EPS
- +504.6%
- Free cash flow
- −4.91%
Quarter to June 2026, against a year earlier
Follow ATNM
Alert me
Actinium Pharmaceuticals, Inc. (ATNM) P/E ratio
As of 6 November 2026, Actinium Pharmaceuticals, Inc. (ATNM) trades at a P/E ratio of 3.9×. Over the past ten years it has ranged from 0.0× (June 2026) to 4.4× (October 2026); the current reading is higher than 100% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 2.7× | — |
| Sep 2025 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BMEA Biomea Fusion, Inc. compare | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. | 3.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)